

Rodent DIPG/DMG Study Quote Request

VCTRONICS is an Ontario, Canada-based medtech company selecting a CRO or academic laboratory to help design and quote the first independent animal validation study for a **coil-based pulsed electromagnetic field exposure platform** in pediatric DIPG/DMG brain tumor models. VCTRONICS will supply the exposure hardware and technical context; the provider is asked to recommend the model, controls, endpoints, timeline and budget.

BRIEF TYPE	REQUESTED INPUT	NEXT STEP
Non-confidential feasibility and quotation request	Study design, animal model and tiered quote	NDA / technical call for device-specific details



Representative vxPEMF exposure hardware

The platform is designed to expose tissue or animal models to controlled pulsed electromagnetic fields. For quotation purposes, treat it as investigational exposure hardware supplied by VCTRONICS. Device specifications and exposure parameters can be reviewed under NDA / technical call.

CONTEXT

Why this request should be routed to an in vivo oncology / neuro-oncology study team.

Scientific input from the provider is central to the request: model selection, endpoints, controls and operational execution should be recommended by the team running the study.

High-need indication DIPG/DMG is a lethal pediatric brain cancer with urgent need for new translational approaches and better preclinical evidence.	First value milestone The immediate objective is a targeted sham-controlled rodent efficacy/safety readout, with optional in vitro work only if it strengthens model selection or dosimetry.	Provider input matters The study should be shaped by model availability, imaging capability, animal ethics / IACUC / ACC path and device-exposure feasibility.
---	--	--

Please recommend and quote the most credible rodent study design.

The central comparison is active vxPEMF exposure versus sham exposure in a relevant DIPG/DMG or orthotopic brain tumor model. Please provide multiple scope tiers instead of a single fixed-budget design. VCTRONICS supplies the device; the provider should advise on animal model, protocol execution and reporting.

Requested first reply

Feasibility, recommended model, quote tiers, expected timeline and next step for NDA or technical call.

STUDY SCOPE

Starting assumptions for the quote.

These are not locked protocol terms. We expect the provider to refine the model, group sizes, endpoints and operational setup.

Protocol elements to assess

- Model:** orthotopic DIPG/DMG mouse or rat model; H3K27M mutant cell line, PDX, or provider-recommended glioma alternative.
- Arms:** active vxPEMF exposure versus sham exposure; optional dose/frequency arms if scientifically justified.
- Scale:** provider-recommended group size, with both lean pilot and statistically stronger proof-of-concept options.
- Device setup:** VCTRONICS supplies exposure hardware; provider advises on cage/exposure configuration, shielding, temperature monitoring and field/dosimetry documentation.
- Study level:** non-GLP proof-of-concept preferred; GLP-style documentation may be quoted separately.

Quote in three tiers

Lean pilot	Lowest credible animal package to test feasibility, operational setup and signal direction.
Standard PoC	Balanced efficacy/safety package with credible controls, survival/tumor burden readouts and a fundable report.
Enhanced	Deeper imaging, histology/IHC, dosimetry detail and GLP-style documentation suitable for follow-on fundraising or grant submission.
Optional add-on	If scientifically recommended, quote in vitro exposure feasibility, DIPG/DMG cell-line selection and dosimetry calibration as a separate pre-study module.

Survival / Kaplan-Meier	Tumor burden by MRI and/or BLI	Histology / IHC
Body weight and tolerability	Temperature / dosimetry monitoring	Final report and raw data package

PROVIDER REPLY

Requested response from your team.

A short feasibility response is enough to start. The goal is to identify the right partner and then move into NDA, protocol refinement and contract terms.

Feasibility	Can your team support a DIPG/DMG or orthotopic brain tumor device-exposure study with external hardware, active exposure and sham conditions?
Model choice	Which model, cell line or PDX would you recommend, and what are the main risks or limitations?
Budget and timeline	Itemized quote by tier, including setup, model initiation, optional in vitro pre-study module, animal ethics / IACUC / ACC, imaging, treatment, histology and final report.
Contract path	NDA, MSA/SRA, data ownership, publication terms, device transfer requirements and next step for a technical call.

Available after NDA / technical call	Device specifications, exposure setup constraints, prior PEMF/Vortex technical documentation, operating-principle schematic, patent summary, draft exposure parameters, sham concept, data ownership and publication preferences.
---	---

Requested response

Please reply with feasibility, recommended model, tiered quote, timeline and next step for NDA / technical call.

COMPANY	CONTACT	EMAIL / PHONE
VCTRONICS Corp. Ontario, Canada	Vladimir Proskurov CEO & Inventor	vladimir@mail.vctrionics.com +1 647 863 5969